Practice Point®: Rare Diseases

In this module, Dr Hirbe reviews clinical case scenarios, key takeaways, and referral framework. Visit the link in our bio to earn FREE AMA, ABS, or ANCC credit!

In this module, Dr. Hirbe dives into RAS signaling Axis, rationale for MEK inhibition, and a high level overview of clinical evidence. Visit the link in our bio to earn FREE AMA, ABS, or ANCC credit!

In this module, Dr. Hirbe provides an overview of NF1-PN, how to recognize NF1-PN, and diagnosing and monitoring patients with NF1-PN. Visit the link in our bio to earn FREE AMA, ABS, or ANCC credit!

Using a realistic patient case, this final episode demonstrates how expert clinicians evaluate, diagnose, and manage a patient with suspected adult HLH in real time. Faculty discuss the interpretation of evolving clinical findings, biomarkers, and imaging, while highlighting common diagnostic pitfalls, treatment escalation strategies, and the importance of identifying the underlying trigger. The c...

Successful management of adult HLH requires simultaneous control of hyperinflammation and identification of the underlying trigger. In this episode, faculty review practical treatment approaches, including corticosteroids, targeted immunomodulatory therapies, and selective use of etoposide-based regimens, while highlighting the growing role of pathway-directed therapies. The discussion emphasizes...

Early recognition is critical to improving outcomes in adult HLH. This episode explores the clinical features, common triggers, and laboratory abnormalities that should raise suspicion for HLH, while reviewing the strengths and limitations of current diagnostic tools, including the HLH-2004 criteria, HScore, and emerging biomarker strategies. Faculty also discuss how trends in ferritin and immune...

Adult hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressive hyperinflammatory syndrome that often presents with nonspecific features, making early diagnosis challenging. In this introductory episode, expert faculty explain the underlying immunobiology of adult HLH, distinguish primary from secondary disease, and explore why HLH should be viewed as a syndrome rather than a single diseas...

Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice. From Refractory to Resolved: Re...

Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice. From Refractory to Resolved: Re...

Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice. From Refractory to Resolved: Re...

These podcast episodes explore the rapidly evolving treatment landscape of Primary Biliary Cholangitis, highlighting recent therapeutic advances and reviews emerging clinical evidence on promising investigational therapies. Designed for healthcare professionals, these episodes provides expert commentary on the latest cutting-edge data presented at EASL Congress 2026. Through an engaging podcast fo...

These podcast episodes explore the rapidly evolving treatment landscape of Primary Biliary Cholangitis, highlighting recent therapeutic advances and reviews emerging clinical evidence on promising investigational therapies. Designed for healthcare professionals, these episodes provides expert commentary on the latest cutting-edge data presented at EASL Congress 2026. Through an engaging podcast fo...

Leveraging emerging evidence presented at AAN, Dr. Angela Hirbe provides synthesis of key findings, highlight their relevance across pediatric and adult care, and frame practical considerations for patient assessment and longitudinal management. Launch/Release Date: April 24, 2026 Activity Expiration Date: March 31, 2027 FACULTY Angela Hirbe, MD, PhD Associate Professor of Medicine and Pediatrics...

Clinical care for myasthenia gravis is entering a period of meaningful progress, with growing opportunities to improve how the disease is diagnosed, assessed, and treated. Increased awareness of disease heterogeneity and the expanding use of standardized severity assessments are helping clinicians better define disease burden and guide management decisions. In this 20-minute podcast episode, Dr. J...

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and...

This activity will inform participants about the complex pathophysiology of NF1-PN and how an understanding of molecular pathways has led to the development of MEK inhibitors. The key published and ongoing clinical evidence on the utility of approved and emerging therapies for NF1-PN will be detailed to provide a strong foundation for clinical decision-making. An in-depth guide to recognize and di...

Gout remains the most common form of inflammatory arthritis in adults, yet it continues to be one of the most misunderstood and mismanaged chronic diseases in clinical practice. Despite clear treatment guidelines and a growing array of therapeutic options, a substantial proportion of patients experience persistent flares, disease progression, and comorbid complications due to clinical inertia, fra...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this podcast activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year. Launch Date: June 5, 2025...